Blog 2

Long term myopia control efficacy of MiSight 1 Day

By Clare Maher | May 21, 2021 | 0 Comments

After the 3-year MiSight 1 day clinical trial, the control group children were switched to MiSight. A ‘virtual control group’ mathematical model, previously published, was utilized to demonstrate a continued myopia control effect across six years, plus effectiveness of treatment for children who commenced wear at age 11-15 years.

Choroidal thickening in response to DIMS spectacle lens wear

By Clare Maher | May 19, 2021 | 0 Comments

This study reported that children wearing DIMS spectacle lenses showed increased sub-foveal choroidal thickness than controls at 1 week which increased in the first 6 months and was maintained at 2 years. There was a correlation between more choroidal thickening and less axial elongation, but choroidal thickening only explained around 8% of the variation in axial length.

Does more peripheral defocus increase the myopia control effect? Evidence from the BLINK study

By Clare Maher | May 19, 2021 | 0 Comments

The BLINK study found that +2.50 Add centre-distance multifocal contact lenses (MFCLs) slowed myopia progression but the +1.50 Add didn’t. Further analysis indicates that increased peripheral defocus created by the +2.50 Add only accounted for around 15% of the myopia control effect, indicating other mechanisms are involved.

Which children are at risk of developing high myopia in their teenage years?

By Clare Maher | May 19, 2021 | 0 Comments

A combination of higher baseline myopia, parental myopia and faster 3-year progression in earlier childhood were strongly predictive of teenage high myopia in this study. Young patients with these combination of factors should receive closer clinical monitoring and timely interventions to slow myopia progression.

Influence of atropine on retinal signaling in a mouse model

By Clare Maher | May 19, 2021 | 0 Comments

This research showed that the concentration of atropine which reaches the retina is 400 times less than by topical administration; and that higher concentrations directly exposed to the mouse retina influence retinal signaling. Whether this is indicates a possible mechanism or unintended impact of atropine, and how this may translate to atropine use in humans, is unknown.

Do myopia controlling spectacles with lenslets affect visual quality?

By Clare Maher | May 19, 2021 | 0 Comments

When looking through the ‘treatment zones’ of three different types of myopia controlling spectacle lenses with lenslets, visual acuity is reduced by 3-5 letters and mid-to-high frequency contrast sensitivity is mildly affected compared to single vision spectacles. We’re yet to learn if small differences between designs may influence patient preference. 

Two year clinical study outcomes for the Defocus Incorporated Multiple Segments (DIMS) spectacle lens

By Clare Maher | April 27, 2021 | 0 Comments

This study reports two year results from a randomized clinical trial examining Defocus Incorporated Multiple Segments (DIMS) spectacle lenses for myopia control. The findings showed around 50% refractive and 60% axial length efficacy in Hong Kong Chinese children, with an absolute effect of 0.44D lower refraction and 0.34mm less axial elongation in DIMS wearers.

MiSight’s Impact on Binocular and Accommodative Function

By Clare Maher | February 12, 2021 | 0 Comments

The purpose of this 2 year study was to determine the effect of MiSight contact lenses used to control myopia on binocular vision and accommodation in children, as compared with children wearing SV spectacles, with the researches finding no significant differences in binocular and accommodative measures between the study groups.

Determining the Optimal Concentration of Atropine

By Clare Maher | February 5, 2021 | 0 Comments

Despite being used for myopia management for many years, significant controversy exists in both literature and clinical optometric practice regarding the optimal concentration of atropine. The LAMP study sheds light on this mystery by investigating efficacy of 0.05%, 0.025% and 0.01% atropine for slowing myopia progression.

Myopia control efficacy of MiSight 1 day over six years

By Clare Maher | January 22, 2021 | 0 Comments

In this review we explore the 6-year results for MiSight 1 day recently presented at the 2020 American Academy of Optometry meeting. Based on the abstract, children who were older at initial fitting (11-15 years) progressed similarly over 3 years to matched children who were treated for 6 years, indicating that older children could still gain a treatment effect from MiSight 1 day.